A new non-pharmacological vacuum therapy for female sexual dysfunction

Kevin Lenuell Billups, Laura Berman, Jennifer Berman, Michael E. Metz, Margaret E. Glennon, Irwin Goldstein

Research output: Contribution to journalArticle

Abstract

Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalJournal of Sex and Marital Therapy
Volume27
Issue number5
StatePublished - 2001
Externally publishedYes

Fingerprint

Vacuum
Orgasm
Arousal
pharmaceutical
Clitoris
Lubrication
Therapeutics
Equipment and Supplies
Aptitude
market
ability
Healthy Volunteers
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Psychology(all)
  • Clinical Psychology

Cite this

Billups, K. L., Berman, L., Berman, J., Metz, M. E., Glennon, M. E., & Goldstein, I. (2001). A new non-pharmacological vacuum therapy for female sexual dysfunction. Journal of Sex and Marital Therapy, 27(5), 435-441.

A new non-pharmacological vacuum therapy for female sexual dysfunction. / Billups, Kevin Lenuell; Berman, Laura; Berman, Jennifer; Metz, Michael E.; Glennon, Margaret E.; Goldstein, Irwin.

In: Journal of Sex and Marital Therapy, Vol. 27, No. 5, 2001, p. 435-441.

Research output: Contribution to journalArticle

Billups, KL, Berman, L, Berman, J, Metz, ME, Glennon, ME & Goldstein, I 2001, 'A new non-pharmacological vacuum therapy for female sexual dysfunction', Journal of Sex and Marital Therapy, vol. 27, no. 5, pp. 435-441.
Billups KL, Berman L, Berman J, Metz ME, Glennon ME, Goldstein I. A new non-pharmacological vacuum therapy for female sexual dysfunction. Journal of Sex and Marital Therapy. 2001;27(5):435-441.
Billups, Kevin Lenuell ; Berman, Laura ; Berman, Jennifer ; Metz, Michael E. ; Glennon, Margaret E. ; Goldstein, Irwin. / A new non-pharmacological vacuum therapy for female sexual dysfunction. In: Journal of Sex and Marital Therapy. 2001 ; Vol. 27, No. 5. pp. 435-441.
@article{09f29e2f3dea48dba9f8993abe9c5268,
title = "A new non-pharmacological vacuum therapy for female sexual dysfunction",
abstract = "Although Female Sexual Dysfunction (FSD) affects 40{\%} of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.",
author = "Billups, {Kevin Lenuell} and Laura Berman and Jennifer Berman and Metz, {Michael E.} and Glennon, {Margaret E.} and Irwin Goldstein",
year = "2001",
language = "English (US)",
volume = "27",
pages = "435--441",
journal = "Journal of Sex and Marital Therapy",
issn = "0092-623X",
publisher = "Routledge",
number = "5",

}

TY - JOUR

T1 - A new non-pharmacological vacuum therapy for female sexual dysfunction

AU - Billups, Kevin Lenuell

AU - Berman, Laura

AU - Berman, Jennifer

AU - Metz, Michael E.

AU - Glennon, Margaret E.

AU - Goldstein, Irwin

PY - 2001

Y1 - 2001

N2 - Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

AB - Although Female Sexual Dysfunction (FSD) affects 40% of American women, there is no FDA-approved pharmaceutical therapy. The EROS-CTD™ (Clitoral Therapy Device, UroMetrics, Inc., St. Paul, MN) treatment is the first FDA cleared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitoral engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study was to assess the effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal volunteers and women with FSD.

UR - http://www.scopus.com/inward/record.url?scp=0034868192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034868192&partnerID=8YFLogxK

M3 - Article

C2 - 11554204

AN - SCOPUS:0034868192

VL - 27

SP - 435

EP - 441

JO - Journal of Sex and Marital Therapy

JF - Journal of Sex and Marital Therapy

SN - 0092-623X

IS - 5

ER -